Chisaroka Echendu
Radiation Oncology · Beaumont, TXNPI 1336404748
Payments from drug & device makers
Across 74 payments — averaging $22.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$192
- Incyte Corporation$144
- Puma Biotechnology, Inc.$133
- Rigel Pharmaceuticals, Inc.$81
- Bayer$76
- Recordati_rare_diseases_inc.$71
- plus $937 from 34 others
What the payments were for
- Food & beverage$1,55595%
- Education$785%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 7 | $192 |
| Incyte Corporation | 6 | $144 |
| Puma Biotechnology, Inc. | 8 | $133 |
| Rigel Pharmaceuticals, Inc. | 3 | $81 |
| Bayer | 4 | $76 |
| Recordati_rare_diseases_inc. | 1 | $71 |
| Merck | 3 | $64 |
| Sanofi | 2 | $57 |
| Immunocore Limited | 2 | $51 |
| Visionrt, Inc. | 1 | $46 |
| Tersera Therapeutics LLC | 2 | $43 |
| Daiichi Sankyo Inc. | 2 | $38 |
| Jazz Pharmaceuticals Inc. | 2 | $37 |
| Olympus America Inc. | 2 | $35 |
| Lilly USA, LLC | 2 | $33 |
| Novocure Inc. | 2 | $31 |
| Eisai Inc. | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Pfizer | 1 | $29 |
| Myovant Sciences Inc. | 1 | $29 |
| AstraZeneca | 1 | $28 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $27 |
| Array Biopharma Inc | 1 | $27 |
| Sobi, Inc | 1 | $26 |
| Deciphera Pharmaceuticals Inc. | 1 | $24 |
| Spectrum Pharmaceuticals Inc. | 1 | $23 |
| Bristol Myers Squibb | 1 | $21 |
| Amgen | 1 | $19 |
| Geron Corporation | 1 | $18 |
| GSK | 1 | $18 |
| Boston Scientific | 1 | $18 |
| ADC Therapeutics America, Inc. | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $17 |
| Mirati Therapeutics, Inc. | 1 | $16 |
| AMAG Pharmaceuticals, Inc. | 1 | $15 |
| Seagen Inc. | 1 | $15 |
| Taiho Oncology, Inc. | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $13 |
| Springworks Therapeutics, Inc. | 1 | $13 |
How this compares
$1,633 in reported general payments places this provider in the 60th percentile of 418 radiation oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 48 | $608 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Beaumont
- Daniel GomezHouston$8.7M
- Neil DesaiDallas$8.6M
- Chad TangHouston$7.7M
- James WelshHouston$5.1M
- Caroline ChungHouston$3.7M
- Karen HoffmanHouston$2.6M
- Clifton FullerHouston$1.6M
- Robert TimmermanDallas$1.5M
- Steven LinHouston$1.5M
- Chenyang WangHouston$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.